EC
LOGC

EcoR1 Capital’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

EcoR1 Capital’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-688,700
Closed -$5.01M – 81
2021
Q1 		$5.01M Sell
688,700
-86,300
-11% -$710K 0.22% 40
2020
Q4 		$5.91M Buy
+775,000
New +$5.18M 0.32% 37

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EcoR1 Capital's LOGC Position: Q2 2021 in Review

EcoR1 Capital sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 688,700 shares — an estimated $5.01M sold.

EcoR1 Capital first reported a position in LOGC in Q4 2020 and held it in 2 quarters. The position peaked at $5.91M in Q4 2020. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • EcoR1 Capital reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • EcoR1 Capital sold 688,700 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $5.01M.
  • EcoR1 Capital first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • EcoR1 Capital's LogicBio Therapeutics, Inc. Common Stock position peaked at $5.91M in Q4 2020.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.